Indoco Remedies' Hyderabad facility clears USFDA inspection with zero Form 483 finding

19 Sep 2022 , 11:40 AM

Indoco Remedies Limited said that the United States Food and Drug Administration (USFDA) examined its AnaCipher Clinical Research Organization in Hyderabad from September 12 to September 16, 2022.

The clinical phase of inspection included three BA/BE studies submitted by clients to the USFDA and was completed satisfactorily with zero 483s.

“This is AnaCipher CRO’s seventh consecutive USFDA inspection with ZERO 483s. We are determined to adhere strictly to all legal laws and regulations, as well as maintain the highest quality standards in providing excellent services to our clients,” stated Aditi Kare Panandikar, Managing Director of Indoco Remedies Limited.

At around 11.38 AM, Indoco Remedies was trading at Rs353.60 down by 0.25% from its previous closing of Rs354.50 on the BSE. The scrip opened at Rs357 and touched intraday high and low of Rs371.65 and Rs350.50 respectively.

For feedback and suggestions, write to us at [e-mail]